temsirolimus

01/15/2011 - "We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. "
01/01/2011 - "Temsirolimus appears to be an effective and well-tolerated substance in the treatment of patients with a good performance status, low MSKCC score and stable disease under previous antiangiogenic treatment in advanced renal cell cancer. "
05/11/2010 - "Temsirolimus was approved in Europe as first-line treatment of poor-prognosis advanced renal cell carcinoma (advRCC) based on significant clinical benefits. "
10/01/2008 - "Temsirolimus demonstrates a significant improvement in overall survival in patients with advanced renal cell carcinoma and poor-prognostic features, thereby validating the importance of mTOR in the natural history of this disease. "
10/01/2019 - "Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. "

01/01/2011 - "Especially patients with a good response to previous antiangiogenic treatment, a good overall condition and a low Memorial Sloan Kettering Cancer Center (MSKCC) score benefited from subsequent treatment with temsirolimus. "
05/15/2014 - "However, the effects of temsirolimus, the only first-generation mTOR inhibitor approved by the FDA for first-line treatment of metastatic RCC, on tumor reduction and progression-free survival are minimal. "
12/01/2015 - "Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors."
01/01/2015 - "Our results indicate some efficacy of temsirolimus in untreated patients with renal tumors and poor-intermediate prognosis, although the limitations of small sample size and retrospective nature must be taken into account. "
01/01/2021 - "Present study showed the feasibility of PDX model to explore the mechanisms of mTOR resistance acquisition and suggested that genetic alterations, including that of DNMT1, which alter the methylation status in cancer cells, are one of the potential mechanisms of developing resistance to temsirolimus."

02/01/2009 - "A prominent member in its class of medications, temsirolimus has already been shown to improve overall survival in advanced kidney cancer, when compared with the previous standard, IFN-alpha. "
01/01/2015 - "The aim of this study was to investigate the outcomes of an unselected group of patients with renal cancer treated with temsirolimus in a compassionate use program. "
08/01/2014 - "Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer."
06/01/2014 - "The procedure is applied to analyze the aforementioned renal cancer study and identify gene transcripts and possible time-interactions that are relevant to CCI-779 metabolism in peripheral blood."
06/15/2004 - "Based on our results, weekly doses of 25, 75, and 250 mg CCI-779 not based on classical definitions of maximum-tolerated dose are being tested in phase II trials in patients with breast and renal cancer."

11/01/2010 - "In this study, we investigated the antitumor effect of temsirolimus-mediated mTOR inhibition against advanced oral squamous cell carcinoma. "
04/01/2015 - "We observed considerable heterogeneity in sensitivity of HNSCC cell lines to CCI-779 monotherapy. "
12/01/2010 - "Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma."
11/01/2010 - "Temsirolimus inhibited the proliferation and migration of HSC-2 oral squamous cell carcinoma cells in vitro and suppressed the growth of oral squamous cell carcinoma xenografts in vivo. "
11/01/2010 - "Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction."

01/01/2019 - "Re: Safety and Efficacy of Temsirolimus as Second Line Treatment for Patients with Recurrent Bladder Cancer."
01/01/2018 - "Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer."
06/04/2019 - "Temsirolimus resistance is associated with reactivation of bladder cancer growth and invasive behavior. "
06/04/2019 - "Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro."
12/15/2017 - "Therefore, the temsirolimus-VPA-combination might be an innovative strategy for bladder cancer treatment."